PMID- 33737451
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20231215
IS  - 2053-8790 (Print)
IS  - 2053-8790 (Electronic)
IS  - 2053-8790 (Linking)
VI  - 8
IP  - 1
DP  - 2021 Mar
TI  - Hydroxychloroquine is associated with lower platelet activity and improved 
      vascular health in systemic lupus erythematosus.
LID - 10.1136/lupus-2021-000475 [doi]
LID - e000475
AB  - OBJECTIVE: Hydroxychloroquine (HCQ) is a mainstay of therapy in the treatment of 
      SLE. The effect of HCQ on platelets and vascular health is uncertain. We 
      investigated the relationship between HCQ use and dose with platelet activity, 
      platelet transcriptomics and vascular health in patients with SLE. METHODS: 
      Platelet aggregation, platelet mRNA expression and vascular health (sublingual 
      capillary perfused boundary region (PBR), red blood cell filling (RBCF) and 
      brachial artery reactivity testing) were analysed by HCQ use and dose. RESULTS: 
      Among 132 subjects with SLE (age: 39.7+/-12.9 years, 97% female), 108 were on HCQ. 
      SLE disease activity was similar between subjects on and off HCQ. Platelet 
      aggregation in response to multiple agonists was significantly lower in patients 
      on HCQ. There were inverse relationships between HCQ dose and gene expression 
      pathways of platelet activity. Gene expression of P-selectin (SELP) was inversely 
      correlated with HCQ dose (r=-0.41, p=0.003), which was validated at the protein 
      level. Subjects on HCQ had improved vascular function correlating with HCQ dose 
      as measured by lower PBR (r=-0.52, p=0.007), higher RBCF (r=0.55, p=0.004) and 
      greater brachial artery reactivity (r=0.43, p=0.056). CONCLUSION: HCQ use was 
      associated with decreased platelet activation and activation-related transcripts 
      and improved vascular health in SLE.
CI  - (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Cornwell, MacIntosh Grant
AU  - Cornwell MG
AUID- ORCID: 0000-0002-3041-4410
AD  - Institute for Systems Genetics, NYU Langone Health, New York City, New York, USA.
AD  - Division of Translational Medicine, New York University School of Medicine, New 
      York City, New York, USA.
FAU - Luttrell-Williams, Elliot S
AU  - Luttrell-Williams ES
AD  - Division of Cardiology, Department of Medicine, New York University Grossman 
      School of Medicine, New York City, New York, USA.
FAU - Golpanian, Michael
AU  - Golpanian M
AD  - Division of Rheumatology, Department of Medicine, New York University School of 
      Medicine, New York City, New York, USA.
FAU - El Bannoudi, Hanane
AU  - El Bannoudi H
AD  - Division of Cardiology, Department of Medicine, New York University Grossman 
      School of Medicine, New York City, New York, USA.
FAU - Myndzar, Khrystyna
AU  - Myndzar K
AD  - Division of Cardiology, Department of Medicine, New York University Grossman 
      School of Medicine, New York City, New York, USA.
FAU - Izmirly, Peter
AU  - Izmirly P
AD  - Division of Rheumatology, Department of Medicine, New York University School of 
      Medicine, New York City, New York, USA.
FAU - Belmont, H Michael
AU  - Belmont HM
AD  - Division of Rheumatology, Department of Medicine, New York University School of 
      Medicine, New York City, New York, USA.
FAU - Katz, Stuart
AU  - Katz S
AD  - Division of Translational Medicine, New York University School of Medicine, New 
      York City, New York, USA.
FAU - Smilowitz, Nathaniel R
AU  - Smilowitz NR
AUID- ORCID: 0000-0002-6823-2815
AD  - Division of Cardiology, Department of Medicine, New York University Grossman 
      School of Medicine, New York City, New York, USA.
FAU - Engel, Alexis
AU  - Engel A
AD  - Division of Rheumatology, Department of Medicine, New York University School of 
      Medicine, New York City, New York, USA.
FAU - Clancy, Robert
AU  - Clancy R
AD  - Division of Rheumatology, Department of Medicine, New York University School of 
      Medicine, New York City, New York, USA.
FAU - Ruggles, Kelly
AU  - Ruggles K
AD  - Institute for Systems Genetics, NYU Langone Health, New York City, New York, USA.
AD  - Division of Translational Medicine, New York University School of Medicine, New 
      York City, New York, USA.
FAU - Buyon, Jill P
AU  - Buyon JP
AD  - Division of Rheumatology, Department of Medicine, New York University School of 
      Medicine, New York City, New York, USA.
FAU - Berger, Jeffrey S
AU  - Berger JS
AUID- ORCID: 0000-0001-8216-4647
AD  - Division of Cardiology, Department of Medicine, New York University Grossman 
      School of Medicine, New York City, New York, USA Jeffrey.Berger@nyumc.org.
LA  - eng
GR  - P50 AR070591/AR/NIAMS NIH HHS/United States
GR  - R01 HL139909/HL/NHLBI NIH HHS/United States
GR  - T32 GM136573/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - Lupus Sci Med
JT  - Lupus science & medicine
JID - 101633705
RN  - 0 (Antirheumatic Agents)
RN  - 4QWG6N8QKH (Hydroxychloroquine)
SB  - IM
MH  - Adult
MH  - Antirheumatic Agents/therapeutic use
MH  - Blood Platelets
MH  - Female
MH  - Humans
MH  - Hydroxychloroquine/therapeutic use
MH  - *Lupus Erythematosus, Systemic/drug therapy
MH  - Male
MH  - Middle Aged
PMC - PMC7978255
OTO - NOTNLM
OT  - cardiovascular diseases
OT  - inflammation
OT  - lupus erythematosus
OT  - systemic
COIS- Competing interests: None declared.
EDAT- 2021/03/20 06:00
MHDA- 2021/09/18 06:00
PMCR- 2021/03/18
CRDT- 2021/03/19 06:36
PHST- 2021/01/07 00:00 [received]
PHST- 2021/02/10 00:00 [revised]
PHST- 2021/02/20 00:00 [accepted]
PHST- 2021/03/19 06:36 [entrez]
PHST- 2021/03/20 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2021/03/18 00:00 [pmc-release]
AID - 8/1/e000475 [pii]
AID - lupus-2021-000475 [pii]
AID - 10.1136/lupus-2021-000475 [doi]
PST - ppublish
SO  - Lupus Sci Med. 2021 Mar;8(1):e000475. doi: 10.1136/lupus-2021-000475.